ThinkingNode.Life
ThinkingNode Life Science, Inc. addresses the unreliability of translating preclinical animal testing to human outcomes in drug R&D, which leads to increased costs, limited results, and ethical concerns due to the annual use of over 115 million animals. Leveraging their next-gen AI, SMARTNet™ (Self-organized Multi-Agent Reasoning Technology Network), ThinkingNode generates advanced mechanistic human digital cell simulations through a Digital Cell Differentiation™ process. This process utilizes patient gene expression data to create highly unique and powerful cell simulations capable of predicting dynamic cellular responses on a scalable digital platform. These simulations can be used before animal testing to improve model selection and compound ranking, thereby reducing trial-and-error in preclinical iterations and saving time and cost. When combined with animal testing, they provide supplemental human-specific data to strengthen animal model results for robust IND-enabling preclinical submissions. ThinkingNode's human digital clones have been successfully applied to cancer and autoimmune disorders. The company's whole-cell-centric approach offers a transformative shift for drug R&D, aiming to make human digital clone simulations systematic for all drug R&D.
ThinkingNode.Life
ThinkingNode Life Science, Inc. addresses the unreliability of translating preclinical animal testing to human outcomes in drug R&D, which leads to increased costs, limited results, and ethical concerns due to the annual use of over 115 million animals. Leveraging their next-gen AI, SMARTNet™ (Self-organized Multi-Agent Reasoning Technology Network), ThinkingNode generates advanced mechanistic human digital cell simulations through a Digital Cell Differentiation™ process. This process utilizes patient gene expression data to create highly unique and powerful cell simulations capable of predicting dynamic cellular responses on a scalable digital platform. These simulations can be used before animal testing to improve model selection and compound ranking, thereby reducing trial-and-error in preclinical iterations and saving time and cost. When combined with animal testing, they provide supplemental human-specific data to strengthen animal model results for robust IND-enabling preclinical submissions. ThinkingNode's human digital clones have been successfully applied to cancer and autoimmune disorders. The company's whole-cell-centric approach offers a transformative shift for drug R&D, aiming to make human digital clone simulations systematic for all drug R&D.